Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
Authors' conclusion
Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia.
Study context
- Population
- Patients with severe hypertriglyceridemia (SHASTA-2) or mixed hyperlipidemia (MUIR)SHASTA-2 and MUIR
- Participants
- 403 patients
- Comparison
- Plozasiran vs placebo
- Primary endpoint
- Lipoprotein particle concentration and subclass distribution by nuclear magnetic resonance (NMR)
Methodological detailsplacebo-controlled, 2 phase 2 studies
- Placebo-controlled
- 2 phase 2 studies
Primary result
As reported in the abstract
Lipoprotein particles by NMR, placebo-adjusted change
- SHASTA-2: total TRL particles (TRL-P) (dose-dependent reduction)
- −46%
- SHASTA-2: large low-density lipoprotein particles (LDL-P)
- +53%
- SHASTA-2: medium LDL-P
- +56%
- SHASTA-2: small LDL-P (trended lower)
- −13%
- SHASTA-2: total HDL-P
- +8%
- SHASTA-2: large HDL-P
- +36%
- MUIR: total TRL-P (pooled plozasiran, significant)
- −48%
- MUIR: large LDL-P
- +88%
- MUIR: medium LDL-P
- +46%
- MUIR: small LDL-P
- −28%
- MUIR: total HDL-P
- +12%
- MUIR: large HDL-P
- +83%
Original publication
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia. J Am Coll Cardiol. Published 17 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →